This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hing, S. Articles by Pritchard-Jones, K. Search for Related Content PubMed PubMed Citation Articles by Hing, S. Articles by Pritchard-Jones, K.

(American Journal of Pathology. 2001;158:393-398.)
© 2001 American Society for Investigative Pathology

Short Communication

Gain of 1q Is Associated with Adverse Outcome in Favorable Histology Wilms’ Tumors

Sandra Hing^*, Yong-Jie Lu^*, Brenda Summersgill, Linda King-Underwood^*, James Nicholson, Paul Grundy^§, Richard Grundy, Manfred Gessler^||, Janet Shipley and Kathy Pritchard-Jones^*

From the Sections of Paediatrics ^*
and Molecular Carcinogenesis,
Institute of Cancer Research/Royal Marsden Hospital NHS Trust, Sutton, Surrey, United Kingdom; the Addenbrookes Hospital,
Cambridge, United Kingdom; the Birmingham Children’s Hospital,
Birmingham, United Kingdom; the Molecular Oncology Program,^§
Cross Cancer Institute, Edmonton, Alberta, Canada; and the Theodor-Boveri-Institut für Biowissenschaften,^||
(Biozentrum) der Universität Würzburg, Germany

Although several genes/genetic loci involved in the etiology of Wilms’ tumor have been identified, little is known of the molecular changes associated with relapse. We therefore undertook an analysis by comparative genomic hybridization (CGH) of 58 tumor samples of favorable histology Wilms’ tumor taken at initial diagnosis and/or relapse. Tumors with anaplastic histology were excluded as this is known to be associated with p53 mutation and a poor prognosis. A control group of 21 Wilms’ tumors that did not relapse was also analyzed. The overall frequency of gains or losses of genetic material detected by CGH was similar in both groups (77% in relapsing tumors and 70% in the nonrelapse group) as was the median number of changes per tumor (relapse group: n = 4, range, 1 to 19; nonrelapse group: n = 3, range, 1 to 8). However, gain of 1q was significantly more frequent in the relapse series [27 of 46 (59%) versus 5 of 21 (24%), P = 0.019]. In 12 matched tumor pairs, the CGH profiles, including 1q gain, were similar at diagnosis and relapse, with little evidence for further copy number changes being involved in clonal evolution. The results suggest that 1q gain at diagnosis could be used to identify patients with favorable histology Wilms’ tumor at increased risk of relapse who might benefit from early treatment intensification.

This article has been cited by other articles:

				J.-P. Kilday, R. Rahman, S. Dyer, L. Ridley, J. Lowe, B. Coyle, and R. Grundy Pediatric Ependymoma: Biological Perspectives Mol. Cancer Res., June 1, 2009; 7(6): 765 - 786. [Abstract] [Full Text] [PDF]

				R Natrajan, W Warren, B Messahel, J S Reis-Filho, M-A Brundler, J S Dome, P E Grundy, G Vujanic, K Pritchard-Jones, and C Jones Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours J. Clin. Pathol., January 1, 2008; 61(1): 95 - 102. [Abstract] [Full Text] [PDF]

				Y. Stewenius, Y. Jin, I. Ora, J. de Kraker, J. Bras, A. Frigyesi, J. Alumets, B. Sandstedt, A. K. Meeker, and D. Gisselsson Defective Chromosome Segregation and Telomere Dysfunction in Aggressive Wilms' Tumors Clin. Cancer Res., November 15, 2007; 13(22): 6593 - 6602. [Abstract] [Full Text] [PDF]

				R. Natrajan, S. E. Little, J. S. Reis-Filho, L. Hing, B. Messahel, P. E. Grundy, J. S. Dome, T. Schneider, G. M. Vujanic, K. Pritchard-Jones, et al. Amplification and Overexpression of CACNA1E Correlates with Relapse in Favorable Histology Wilms' Tumors Clin. Cancer Res., December 15, 2006; 12(24): 7284 - 7293. [Abstract] [Full Text] [PDF]

				M. L. Metzger and J. S. Dome Current Therapy for Wilms' Tumor Oncologist, November 1, 2005; 10(10): 815 - 826. [Abstract] [Full Text] [PDF]

				T. Schlomm, B. Gunawan, H.-J. Schulten, B. Sander, K. Thangavelu, N. Graf, I. Leuschner, R.-H. Ringert, and L. Fuzesi Effects of Chemotherapy on the Cytogenetic Constitution of Wilms' Tumor Clin. Cancer Res., June 15, 2005; 11(12): 4382 - 4387. [Abstract] [Full Text] [PDF]

				W. Li, P. Kessler, H. Yeger, J. Alami, A. E. Reeve, R. Heathcott, J. Skeen, and B. R.G. Williams A Gene Expression Signature for Relapse of Primary Wilms Tumors Cancer Res., April 1, 2005; 65(7): 2592 - 2601. [Abstract] [Full Text] [PDF]

				S. Dyer, E. Prebble, V. Davison, P. Davies, P. Ramani, D. Ellison, and R. Grundy Genomic Imbalances in Pediatric Intracranial Ependymomas Define Clinically Relevant Groups Am. J. Pathol., December 1, 2002; 161(6): 2133 - 2141. [Abstract] [Full Text] [PDF]